TORONTO, May 8, 2017 /PRNewswire/ - Portage Biotech Inc.
("Portage") (OTCQB: PTGEF, Canadian Stock Exchange: PBT.U) would like to inform that it holds 6,341,500 common shares in
Biohaven Pharmaceutical Holding Company Ltd.
Portage currently has 260,688,894 issued and outstanding shares and 281,006,088 fully diluted shares.
Biohaven is a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting
neurological diseases, including rare disorders. Biohaven has licensed intellectual property from companies and institutions
including Bristol-Myers Squibb Company, AstraZeneca AB, Yale University, Catalent, ALS Biopharma LLC
and Massachusetts General Hospital. Biohaven is a company organized under the laws of the British
Virgin Islands and its United States operations are based in New Haven, Connecticut and is listed and traded on New York Stock Exchange under the trading symbol
BHVN.
About Portage
Portage is engaged in the discovery and development of pharmaceutical and biotech products through clinical "proof of concept"
with a focus on areas of unmet clinical need. Following proof of concept, Portage will seek to sell or license these products to
large pharmaceutical or biotechnology companies for further development and commercialization. Portage has an interest in novel
targeted therapies, stem cell therapies, and new indications for older marketed products that have been found to have novel
patentable characteristics that bring new value to patients.
Forward-Looking Statements
This news release includes forward-looking statements within the meaning of the U.S. federal and Canadian securities laws. Any
such statements reflect Portage's current views and assumptions about future events and financial performance. Portage cannot
assure that future events or performance will occur. There are important risks and other factors that could cause actual results
or events to differ materially from those indicated in our forward-looking statements.
Portage assumes no obligation for, and expressly disclaims any duty to update, the information in this News Release.
SOURCE Portage Biotech Inc.